Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy

Cladribine (CLAD) is a lymphodepleting agent approved for active relapsing multiple sclerosis (MS). The impact of CLAD on the adaptive humoral immune system has not sufficiently been studied. This study aimed to assess the influence of CLAD treatment on specific antibody titers to common pathogens....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tobias Moser, Ciara O’Sullivan, Christian Puttinger, Julia Feige, Georg Pilz, Elisabeth Haschke-Becher, Janne Cadamuro, Hannes Oberkofler, Wolfgang Hitzl, Andrea Harrer, Jörg Kraus, Eugen Trinka, Peter Wipfler
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	vaccination lymphodepletion immune reconstitution titers immunization antibody levels Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/28d8262f759248cb881756d95757c55c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:28d8262f759248cb881756d95757c55c
record_format	dspace
spelling	oai:doaj.org-article:28d8262f759248cb881756d95757c55c2021-11-25T16:49:20ZPre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy10.3390/biomedicines91115842227-9059https://doaj.org/article/28d8262f759248cb881756d95757c55c2021-10-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1584https://doaj.org/toc/2227-9059Cladribine (CLAD) is a lymphodepleting agent approved for active relapsing multiple sclerosis (MS). The impact of CLAD on the adaptive humoral immune system has not sufficiently been studied. This study aimed to assess the influence of CLAD treatment on specific antibody titers to common pathogens. We included 18 MS patients treated with CLAD. Serum IgG antibody levels to measles, mumps, rubella, hepatitis B and varicella zoster virus (VZV), as well as diphtheria and tetanus toxins, were measured prior to the initiation of treatment and at 12 and 24 months after first CLAD administration. Moreover, specimens were longitudinally analyzed regarding absolute blood concentrations of IgG and main lymphocyte subsets. No reduction in antibody levels against measles, mumps, rubella, VZV, hepatitis B, diphtheria toxin and tetanus toxin associated with CLAD treatment was observed. Loss of seroprotection occurred in <1%. We found no significant impact of CLAD on absolute serum IgG levels. Absolute lymphocyte counts were significantly reduced at the end of each treatment year (<i>p</i> < 0.00001 and <i>p</i> < 0.000001). This study suggests that CLAD does not interfere with the pre-existing humoral immunologic memory in terms of pathogen-specific antibody titers.Tobias MoserCiara O’SullivanChristian PuttingerJulia FeigeGeorg PilzElisabeth Haschke-BecherJanne CadamuroHannes OberkoflerWolfgang HitzlAndrea HarrerJörg KrausEugen TrinkaPeter WipflerMDPI AGarticlevaccinationlymphodepletionimmune reconstitutiontitersimmunizationantibody levelsBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1584, p 1584 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	vaccination lymphodepletion immune reconstitution titers immunization antibody levels Biology (General) QH301-705.5
spellingShingle	vaccination lymphodepletion immune reconstitution titers immunization antibody levels Biology (General) QH301-705.5 Tobias Moser Ciara O’Sullivan Christian Puttinger Julia Feige Georg Pilz Elisabeth Haschke-Becher Janne Cadamuro Hannes Oberkofler Wolfgang Hitzl Andrea Harrer Jörg Kraus Eugen Trinka Peter Wipfler Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy
description	Cladribine (CLAD) is a lymphodepleting agent approved for active relapsing multiple sclerosis (MS). The impact of CLAD on the adaptive humoral immune system has not sufficiently been studied. This study aimed to assess the influence of CLAD treatment on specific antibody titers to common pathogens. We included 18 MS patients treated with CLAD. Serum IgG antibody levels to measles, mumps, rubella, hepatitis B and varicella zoster virus (VZV), as well as diphtheria and tetanus toxins, were measured prior to the initiation of treatment and at 12 and 24 months after first CLAD administration. Moreover, specimens were longitudinally analyzed regarding absolute blood concentrations of IgG and main lymphocyte subsets. No reduction in antibody levels against measles, mumps, rubella, VZV, hepatitis B, diphtheria toxin and tetanus toxin associated with CLAD treatment was observed. Loss of seroprotection occurred in <1%. We found no significant impact of CLAD on absolute serum IgG levels. Absolute lymphocyte counts were significantly reduced at the end of each treatment year (<i>p</i> < 0.00001 and <i>p</i> < 0.000001). This study suggests that CLAD does not interfere with the pre-existing humoral immunologic memory in terms of pathogen-specific antibody titers.
format	article
author	Tobias Moser Ciara O’Sullivan Christian Puttinger Julia Feige Georg Pilz Elisabeth Haschke-Becher Janne Cadamuro Hannes Oberkofler Wolfgang Hitzl Andrea Harrer Jörg Kraus Eugen Trinka Peter Wipfler
author_facet	Tobias Moser Ciara O’Sullivan Christian Puttinger Julia Feige Georg Pilz Elisabeth Haschke-Becher Janne Cadamuro Hannes Oberkofler Wolfgang Hitzl Andrea Harrer Jörg Kraus Eugen Trinka Peter Wipfler
author_sort	Tobias Moser
title	Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy
title_short	Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy
title_full	Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy
title_fullStr	Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy
title_full_unstemmed	Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy
title_sort	pre-existing humoral immunological memory is retained in patients with multiple sclerosis receiving cladribine therapy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/28d8262f759248cb881756d95757c55c
work_keys_str_mv	AT tobiasmoser preexistinghumoralimmunologicalmemoryisretainedinpatientswithmultiplesclerosisreceivingcladribinetherapy AT ciaraosullivan preexistinghumoralimmunologicalmemoryisretainedinpatientswithmultiplesclerosisreceivingcladribinetherapy AT christianputtinger preexistinghumoralimmunologicalmemoryisretainedinpatientswithmultiplesclerosisreceivingcladribinetherapy AT juliafeige preexistinghumoralimmunologicalmemoryisretainedinpatientswithmultiplesclerosisreceivingcladribinetherapy AT georgpilz preexistinghumoralimmunologicalmemoryisretainedinpatientswithmultiplesclerosisreceivingcladribinetherapy AT elisabethhaschkebecher preexistinghumoralimmunologicalmemoryisretainedinpatientswithmultiplesclerosisreceivingcladribinetherapy AT jannecadamuro preexistinghumoralimmunologicalmemoryisretainedinpatientswithmultiplesclerosisreceivingcladribinetherapy AT hannesoberkofler preexistinghumoralimmunologicalmemoryisretainedinpatientswithmultiplesclerosisreceivingcladribinetherapy AT wolfganghitzl preexistinghumoralimmunologicalmemoryisretainedinpatientswithmultiplesclerosisreceivingcladribinetherapy AT andreaharrer preexistinghumoralimmunologicalmemoryisretainedinpatientswithmultiplesclerosisreceivingcladribinetherapy AT jorgkraus preexistinghumoralimmunologicalmemoryisretainedinpatientswithmultiplesclerosisreceivingcladribinetherapy AT eugentrinka preexistinghumoralimmunologicalmemoryisretainedinpatientswithmultiplesclerosisreceivingcladribinetherapy AT peterwipfler preexistinghumoralimmunologicalmemoryisretainedinpatientswithmultiplesclerosisreceivingcladribinetherapy
_version_	1718412882939478016

Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy

Ejemplares similares